← Back to headlines
FDA Panel Rejects AstraZeneca Cancer Drug, Stock Falls
An FDA advisory committee has voted against endorsing AstraZeneca's new breast cancer drug, camizestrant, leading to a decline in the company's stock. This decision marks a significant setback for the pharmaceutical giant's new treatment.
Sources
Showing 0 of 2 sources
No articles available in your preferred languages.
2 articles available in other languages below.
cnbcCatalan100d ago
AstraZeneca stock falls after FDA panel votes against new cancer drug
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
Read full article →seeking-alphaSpanish100d ago
AstraZeneca hits setback as FDA committee declines to endorse camizestrant
Read full article →Coverage Timeline
First report: seeking-alpha · 30 Apr, 17:36|Full coverage: 2 · 16h|Window: 16h
